enzalutamide,talazoparib
astellas,pfizer
['brca']
 do we agree with the conclusions? the rpfs benefit for brca mutated patients is clear (brca2 being dominant i presume). hrr? isn t the benefit driven by brca 
Medical oncologist. Views my own. Retweets are not an endorsement.